Elevation Oncology to Present at the Piper Sandler 36th Annual Healthcare Conference
Elevation Oncology (Nasdaq: ELEV) has announced its participation in the Piper Sandler 36th Annual Healthcare Conference.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Elevation Oncology (Nasdaq: ELEV) has announced its participation in the Piper Sandler 36th Annual Healthcare Conference. Joseph J. Ferra, President and Chief Executive Officer, will engage in a fireside chat on Tuesday, December 3, 2024, at 8:30 a.m. ET. The company, which specializes in developing selective cancer therapies for patients with solid tumors, will provide a live webcast of the event, accessible through their Investor Relations website. A replay will also be available for those unable to attend the live presentation.
Details
News Market Reaction – ELEV
The recorded move for ELEV in the trading session of this news was +2.89%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
A live webcast and replay of the event will be available on the Events page of the Company's Investor Relations website at https://investors.elevationoncology.com.
About Elevation Oncology, Inc.
Elevation Oncology is an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. We are leveraging our antibody-drug conjugate (ADC) expertise to advance a novel pipeline, initially targeting two clinically validated targets in oncology, Claudin 18.2 and HER3. Our lead candidate, EO-3021, is a potential best-in-class, Claudin 18.2 ADC and is currently being evaluated in the dose expansion portion of a Phase 1 trial (NCT05980416) in patients with advanced, unresectable or metastatic gastric/gastroesophageal adenocarcinoma that express Claudin 18.2. Additionally, we expect to nominate a development candidate for our second program, a HER3-targeting ADC for the treatment of patients with solid tumors that overexpress HER3, in 2024. For more information, visit www.ElevationOncology.com.
Elevation Oncology Investor and Media Contact
Gracie Tong
Senior Director, Investor Relations and Corporate Communications
gtong@elevationoncology.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/elevation-oncology-to-present-at-the-piper-sandler-36th-annual-healthcare-conference-302314303.html
SOURCE Elevation Oncology
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.